Yahoo India Web Search

Search results

  1. People also ask

  2. www.agilent.com › en › avidabiomedAvida Biomed - Agilent

    Mass spectrometry, chromatography, spectroscopy, software, dissolution, sample handling and vacuum technologies courses. Live or on-demand webinars on product introductions, applications and software enhancements. Worldwide trade shows, conferences, local seminars and user group meetings.

  3. Jan 4, 2023 · Avida Biomed’s technology will enable scientists working in precision medicine to develop new approaches for a variety of applications including biomarker discovery, patient selection for clinical trials, diagnosis and prognosis, therapy selection, and disease recurrence.

  4. Jan 4, 2023 · Avida Biomed’s technology will enable scientists working in precision medicine to develop new approaches for a variety of applications including biomarker discovery, patient selection for...

  5. Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.

  6. Jan 4, 2023 · Agilent Technologies announced the acquisition of Avida Biomed, an early stage life sciences company, on Jan. 4, 2022. This acquisition grants Agilent access to Avida’s high-performance enrichment workflows, which are designed to enable clinical researchers to use next-generation sequencing (NGS) approaches for studying cancer.

  7. Jan 5, 2023 · Avida Biomed’s innovative genomics tools enable simultaneous genomic and DNA methylation profiling from a single sample without compromising sensitivity or specificity. The company’s streamlined assay protocol, which also includes library preparation, can be completed in a single shift enabling fast turnaround of assay results.

  8. Jan 6, 2023 · Agilent Technologies Inc. (NYSE: A) announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.